Format

Send to

Choose Destination
See comment in PubMed Commons below
BMJ Case Rep. 2014 Jun 3;2014. pii: bcr2013010247. doi: 10.1136/bcr-2013-010247.

Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab.

Author information

1
Royal Victoria Hospital, Belfast, UK.
2
Centre for Vision and Vascular Science, Queen's University, Belfast, UK.
3
Regional Nephrology Unit, Belfast City Hospital, Belfast, UK.

Abstract

Membranoproliferative glomerulonephritis type II (MPGN II) is characterised by electron-dense deposits of complement components in the glomerular basement membrane and retinal pigment epithelium. Approximately, 10% of affected individuals develop serious ocular complications similar to age-related macular degeneration such as choroidal neovascularisation (CNV), which has been managed with photocoagulation or photodynamic therapy; however, these treatments can impact visual acuity. We report the case of a 42-year-old woman with MPGN II presenting with decreased visual acuity and paracentral scotoma in her left eye due to an extrafoveal choroidal neovascular membrane (growth of new vessels under the retina). The patient was successfully treated with intravitreal ranibizumab (Lucentis) with restoration of visual function. This case highlights the successful management of CNV secondary to MPGN II with the antivascular endothelial growth factor agent ranibizumab and emphasises the importance of early referral of patients with MPGN II who are reporting of visual 'distortion'.

PMID:
24895384
PMCID:
PMC4054119
DOI:
10.1136/bcr-2013-010247
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center